tau imaging news will change little for most memory-clinic patients now, but it sharpens follow-up choices in selected workups. Tau PET means a brain scan that shows tau tangles, twisted proteins tied to Alzheimer's memory loss. Clinics will still reserve scans for people with measurable impairment where Alzheimer's is suspected. Access, out-of-pocket cost, and clear follow-up questions matter more than the tracer name.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the new approval adds
- Who may be considered for tau PET?
- Access and cost to plan for
- Follow-up questions to bring
What the new approval adds
Lantheus Holdings states in the FDA approval notice that the FDA approved Tauklarify on Aug. 14, 2026. The approval covers brain PET in cognitively impaired adults evaluated for Alzheimer's to identify tau tangles.
Lantheus Holdings also notes limits for this use. Safety and effectiveness are not established for non-Alzheimer's tau diseases, and a negative scan does not rule out tau pathology. Your doctor must match the scan to your symptoms and other test results.
Who may be considered for tau PET?
The Alzheimer's Association states in its criteria update that tau PET fits five scenarios only when Alzheimer's is a suspected cause of impairment. It does not fit screening of people without symptoms.
In practice, the path starts with memory testing, medical history, and often blood or amyloid tests. Your clinic decides whether tau imaging would change diagnosis, staging, or treatment advice. If it would not change care, the clinic may skip it.
Access and cost to plan for
Lantheus Holdings notes in its availability update that near-term work will support therapeutic programs while broader commercial availability is assessed. Ask your clinic about referral centers, wait times, and scheduling steps.
As a nearby cost reference, HelpDementia.com reports in its PET cost guide that amyloid PET averages about $3,000 freestanding and $3,000 to $6,000 hospital-based. The same guide notes Medicare patients owe deductible plus about 20% coinsurance when PET is covered. Call your plan for tau PET benefits, prior approval, and written estimates.
Follow-up questions to bring
Use your return visit to link scan results to care choices. Bring a companion, a symptom timeline, and your medication list.
Ask how results will be shared, stored, and used to guide support and safety planning. Bring insurance details and ask for the referral order and estimate before you leave.
- Do my symptoms and other results point to Alzheimer's as the likely cause?
- Would tau PET change my diagnosis, stage, trial options, or treatment?
- Where do I go for the scan, how long is the wait, and how do I prepare?
- What will I owe after insurance, and what approval is needed?
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
